Safety and efficacy of transurethral holmium laser enucleation of the prostate versus bipolar transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: a prospective randomized controlled trial.


Journal

Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285

Informations de publication

Date de publication:
19 Oct 2024
Historique:
received: 28 06 2024
accepted: 03 10 2024
medline: 19 10 2024
pubmed: 19 10 2024
entrez: 19 10 2024
Statut: epublish

Résumé

To evaluate the safety and efficacy of transurethral holmium laser enucleation of the prostate (HoLEP) compared to bipolar transurethral resection of the prostate (bTUR-P) in the treatment of benign prostatic hyperplasia (BPH). A total of 220 BPH patients hospitalized from January 2022 to September 2023 were included in this study. These patients were randomly assigned to HoLEP and bTUR-P groups, with 110 participants in each group. We collected preoperative general information, perioperative data, complications, and postoperative follow-up indicators from both groups of patients. The baseline characteristics of patients in both groups were similar, with no statistical significance (P > 0.05). Compared to the bTUR-P group, the HoLEP group exhibited significantly less intraoperative bleeding (P < 0.001), shorter bladder irrigation time (P = 0.002), shorter catheter retention time (P < 0.001), and reduced postoperative hospitalization (P = 0.002). Additionally, the pain score during urination after catheter removal was significantly lower in the HoLEP group (P < 0.001). Postoperative complications occurred in both groups; however, they were less frequent in the HoLEP group (4 cases), primarily consisting of urinary retention and postoperative bleeding. The bTUR-P group experienced more complications (9 cases). Significant reductions in postoperative residual urine volume (RUV) were observed in both groups (P < 0.001). Both groups also showed significant improvements in Quality of Life (QoL) scores and International Prostate Symptom Scores (IPSS), with the HoLEP group demonstrating a more significant decrease in IPSS (P < 0.001). After comprehensive evaluation, HoLEP was superior to bTUR-P in terms of safety and efficacy. Therefore, HoLEP may be a preferable choice for the treatment of BPH.

Identifiants

pubmed: 39425787
doi: 10.1007/s00423-024-03499-2
pii: 10.1007/s00423-024-03499-2
doi:

Types de publication

Journal Article Randomized Controlled Trial Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

313

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

F A A, A T, A A M et al (2024) Publisher Correction: Examining the prevalence of obesity in school children through an on-site obesity outpatient clinics survey based on student’s lifestyles. Eur Rev Med Pharmacol Sci.; 28(10)
Bryn ML, Kevin M, William TR, Granville AL (2020) L. The rising worldwide impact of benign prostatic hyperplasia. BJU Int.; 127(6)
C D S SJB, W P C (1984) E L L. The development of human benign prostatic hyperplasia with age. J Urol.; 132(3)
Debra EI, Ian M, Steinar H et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol.; 50(6)
Kellogg J, Jaclyn PB, Jonathan S, Elizabeth B-C (2008) Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology.; 72(2)
Conor MD, Matthew S, Norman SM (2020) J. Benign prostatic hyperplasia - what do we know? BJU Int.; 127(4)
Rana BB, H Khaled M, Imman M (2022) M, Development and optimization of a tamsulosin nanostructured lipid carrier loaded with saw palmetto oil and pumpkin seed oil for treatment of benign prostatic hyperplasia. Drug Deliv.; 29(1)
D M R LVSVA et al (2023) Minimally invasive treatment in Benign Prostatic Hyperplasia (BPH). Technol Cancer Res Treat.; 22(0)
John TW, Elizabeth C, Steven J (2008) J. Urologic diseases in America project: benign prostatic hyperplasia. J Urol.; 179(0)
Yu Xi Terence L, Wei Jing C, Kelven S, Liang C, Wei Jin (2019) Is transurethral needle ablation of prostate out of fashion? Outcomes of single session office-based transurethral needle ablation of prostate in patients with symptomatic benign prostatic hyperplasia. Investig Clin Urol.; 60(5)
Juan Va F, Jae Hung J, Mari I et al (2021) Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis. Cochrane Database Syst Rev.; 7(7)
Weixiang H, Han X, Daoquan L et al (2020) Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder. J Cell Mol Med.; 24(22)
Jung Ki J, Hwanik K, Woo Jin B, Cheol Young O, Jin Seon C, Myungsun S (2023) Effect of diabetes Mellitus on symptomatic improvement after surgery for Benign Prostatic Hyperplasia in patients with lower urinary tract Symptom and its relations with Prostatic Urethral Angulation. Int Neurourol J.; 27(2)
Shu-Chuan W, Shu-Han T, Han-Yu T et al (2023) Simple and convenient method for assessing the severity of bleeding during endoscopic prostate surgery and the relationships between its corresponding Surgical outcomes. Diagnostics (Basel).; 13(4)
Ömer T, Ahmet E, Omer B et al (2023) Correlation of postoperative outcomes according to the Amount of Prostatic Tissue Removed in patients undergoing transurethral resection of the prostate. Cureus.; 15(1)
Qi J, En-Guang Y, Yun-Xin Z et al (2022) Transurethral plasmakinetic resection versus enucleation for benign prostatic hyperplasia: comparison of intraoperative safety profiles based on endoscopic surgical monitoring system. BMC Urol.; 22(1)
Chong-Yi Y, Ge-Ming C, Yue-Xiang W et al (2023) Clinical efficacy and complications of transurethral resection of the prostate versus plasmakinetic enucleation of the prostate. Eur J Med Res.; 28(1)
Sun-Tae A, Dong-Hyun L, Sun-Bum C et al (2022) Is prostate urethral lift effective in patients with multiple comorbidities? J Clin Med.; 11(7)
Priyanka R, Alok S, Ishwar D, Sanjeet RS (2018) Comparison of safety, efficacy and cost effectiveness of Photoselective vaporization with bipolar vaporization of prostate in Benign Prostatic Hyperplasia. Curr Urol.; 11(2)
Xian-Tao Z, Ying-Hui J, Tong-Zu L et al (2022) Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition). Mil Med Res.; 9(1)
Jingchao W, Shigeng Z, Bohan W et al (2022) A multicenter retrospective study of transurethral prostate split for benign prostate hyperplasia. Transl Androl Urol.; 11(2)
Yunwu H, Degang C, Xudong S, Yang C, Zongyao H (2023) No bladder irrigation versus continuous bladder irrigation after HoLEP: a propensity score matching analysis. BMC Urol.; 23(1)
Alexander T, Thilo W, Melanie S et al (2021) Holmium laser enucleation of the prostate: A truly size-independent method? Low Urin Tract Symptoms.; 14(1)
W M N MKHB et al (2022) Learning curve and functional outcomes after laser enucleation of the prostate for benign prostate hyperplasia according to surgeon’s caseload. World J Urol.; 40(12)
K K PJG, D A K, T D, F M R (1998) Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J Endourol.; 12(5)
Casabé A, Roehrborn C, Pozzo LD et al (2014) Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 191(3):727–733
doi: 10.1016/j.juro.2013.09.059 pubmed: 24096118
Peng B, Wang G, Zheng J et al (2013) A comparative study of thulium laser resection of the prostate and bipolar transurethral plasmakinetic prostatectomy for treating benign prostatic hyperplasia. BJU Int 111(4):633–637
doi: 10.1111/j.1464-410X.2012.11610.x pubmed: 23107074
Decao H, Wang J, Huang Y et al (2015) Comparison between thulium laser resection of prostate and transurethral plasmakinetic resection of prostate or transurethral resection of prostate. Sci Rep 5:14542
doi: 10.1038/srep14542 pubmed: 26444930 pmcid: 4595764
Tamalunas A, Westhofen T, Schott M et al (2021) The clinical value of holmium laser enucleation of the prostate in octogenarians. Lower Urinary Tract Symptoms 13(2):279–285
doi: 10.1111/luts.12366 pubmed: 33260275
Shvero A, Calio B, Humphreys M, Das A (2021) HoLEP: the new gold standard for surgical treatment of benign prostatic hyperplasia. Can J Urol 28:6–10
pubmed: 34453422
Panagiotis K, Theodoros S, Angelis P, Bhaskar S, Evangelos L (2023) Salvage holmium laser enucleation of the prostate after previous interventions: a systematic review. BJU Int; 133(2)
Mohamed E, James R, Marawan ET (2022) M. Urethral complications Post-holmium Laser Enucleation of the prostate: a seven-year experience. J Endourol.; 36(12)
Akhil KD, Timothy H, Thomas MH (2020) J. Holmium laser enucleation of the prostate (HoLEP): size-independent gold standard for surgical management of benign prostatic hyperplasia. Can J Urol.; 27(0)
Wu Y, Tang X, Shao W, Lu Y (2019) Effect of CT manifestations of cholesteatoma on MMP-2, MMP-9 and IL-6 in the serum of patients. Experimental Therapeutic Med 17(6):4441–4446
Sun N, Fu Y, Tian T et al (2014) Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a randomized clinical trial. Int Urol Nephrol 46(7):1277–1282
doi: 10.1007/s11255-014-0646-9 pubmed: 24492988
Bhandarkar A, Patel D (2022) Comparison of Holmium Laser Enucleation of the prostate with bipolar plasmakinetic enucleation of the prostate: a randomized, prospective controlled trial at Midterm Follow-Up. J Endourol 36(12):1567–1574
doi: 10.1089/end.2022.0449 pubmed: 35943885
Hakenberg OW, Helke C, Manseck A, Wirth MP (2001) Is there a relationship between the amount of tissue removed at transurethral resection of the prostate and clinical improvement in benign prostatic hyperplasia. Eur Urol 39(4):412–417
doi: 10.1159/000052478 pubmed: 11306879
Magdy AE, Hammouda S, Alaa H (2010) A. Holmium laser enucleation versus transurethral resection of the prostate. Can J Urol.; 17(6)
Ajay B, Dipen P (2022) Comparison of Holmium Laser Enucleation of the prostate with bipolar plasmakinetic enucleation of the prostate: a randomized, prospective controlled trial at Midterm Follow-Up. J Endourol.; 36(12)
Chenglou Z, Junhong W, Qiong W (2023) D Mingxu. Safety and Efficacy of Carbon nanoparticle-labeled Lymph Node Dissection in Radical Resection of Gastric Cancer: a systematic review and Meta-analysis. Technol Cancer Res Treat.; 22(0)
Nao S, Yaowen F, Tengzheng T et al (2014) Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a randomized clinical trial. Int Urol Nephrol.; 46(7)
Wei Z, Tao Y, Gu M et al (2021) vsPlasma Kinetic Enucleation Holmium Laser Enucleation for treating Benign Prostatic Hyperplasia: a randomized controlled trial with a 3-Year Follow-Up. J Endourol 35(10):1533–1540
doi: 10.1089/end.2021.0086 pubmed: 33779288
Suh J, Choo M, Oh S (2023) Efficacy and safety of low power holmium laser enucleation of the prostate: a prospective short- and medium-term single-blind randomized trial. Invest Clin Urol 64(5):480–488
doi: 10.4111/icu.20230017
Chen Y, Chen Q, Wang Z et al (2013) A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup. J Urol 189(1):217–222
doi: 10.1016/j.juro.2012.08.087 pubmed: 23174256
Enmar H, Mohamed Fathi A, Mohammed Said E et al (2021) Holmium laser enucleation versus bipolar resection in the management of large-volume benign prostatic hyperplasia: a randomized controlled trial. Int J Urol.; 29(2)
Silin W, Yonggang S, Heng C et al (2023) Pulmonary function protection by single-port thoracoscopic segmental lung resection in elderly patients with IA non-small cell lung cancer: a differential matched analysis. Med (Baltim).; 102(17)
Wenhao T, Jingfu L, Wenju L, Jianping J, Meimei C, Weidong Z (2023) Short-term outcomes of reduced-port laparoscopic surgery versus conventional laparoscopic surgery for total gastrectomy: a single-institute experience. BMC Surg.; 23(1)
Bo P, Jianhua H, Guangchun W, Haimin Z, Min L (2016) Transurethral enucleation of prostate with button electrode plasmakinetic vaporization for the treatment of Benign Prostatic Hyperplasia. Sci Rep; 6(0)
Xin H, Xi Xiang C, Xu C et al (2023) Feasibility of anterior lobe-preserving transurethral enucleation and resection of prostate on improving urinary incontinence in patients with benign prostatic hyperplasia: a retrospective cohort study. Med (Baltim).; 102(7)
Zhang Y, Yuan P, Ma D et al (2019) Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. Prostate Cancer Prostatic Dis 22(4):493–508
doi: 10.1038/s41391-019-0135-4 pubmed: 30816336
Huang S, Tsai C, Tseng C et al (2019) Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. BMJ. 367:l5919
Guoyun Z, Jinkui H, Guangyi H, Ligang R, Wensong Z, Wei W (2022) Efficacy and safety of Transurethral Columnar Balloon Dilation of the prostate for the treatment of Benign Prostatic Hyperplasia: a Multicenter Trial. Comput Math Methods Med.; 2022(7881247)
Dmitry E, Mark T, Andrey M et al (2020) Long-term outcomes of Holmium Laser Enucleation of the prostate: a 5-Year single-center experience. J Endourol.; 34(10)

Auteurs

Bin Jiang (B)

Department of Urology, Haiyan People's Hospital, Haiyan, Zhejiang, 314300, China.

Ping Liang (P)

Department of Urology, Haiyan People's Hospital, Haiyan, Zhejiang, 314300, China.

Yanlei Wu (Y)

Department of Urology, Haiyan People's Hospital, Haiyan, Zhejiang, 314300, China.

Wenmin Wang (W)

The Yangtze River Delta Biological Medicine Research and Development Center of Zhejiang Province, Yangtze Delta Region Institution of Tsinghua University, Hangzhou, Zhejiang, 314006, China.

Liping Shen (L)

Department of Urology, Haiyan People's Hospital, Haiyan, Zhejiang, 314300, China. slpabcd@outlook.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH